Skip to main content
SpringerLink
Log in

Schizophrenia

  • Chapter
  • First Online:
Handbook of Psychiatric Disorders in Adults in the Primary Care Setting

Part of the book series: Current Clinical Practice ((CCP))

  • 418 Accesses

Abstract

While very few healthcare professionals are trained in the diagnosis and treatment of psychotic disorders, most will encounter patients with schizophrenia in clinical practice. Ideally, these patients will be in treatment with a behavioral health team, including a psychiatrist, therapists, nurses, and other professionals working to not only stabilize the patient but promote quality of life and community integration. However, primary care physicians (PCPs) not uncommonly will be the first to tentatively diagnose this disorder in their patients and work up the patients for other causes of psychosis. Sometimes, in situations of medical scarcity, PCPs will also treat schizophrenia. Given these challenges, this chapter first introduces schizophrenia and related psychotic disorders, reviewing key information on epidemiology, illness course, diagnostic criteria, and common clinical presentations. Medical comorbidities, which are frequent in this population, are also reviewed, as are considerations about when to refer to specific medical specialists. Finally, both psychopharmacologic, psychosocial, and psychotherapeutic treatments are reviewed, including considerations for treating acute versus stable patients and recommendations for approaching treatment given patient clinical status and medication side effect burden. While such information is critical for PCP initiated treatment of schizophrenia spectrum disorders, it can also be useful in collaborating with psychiatrists and other members of a behavioral health treatment team, which is highly recommended in this medically underserved population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Addington J, Van Mastrigt S, Addington D. Duration of untreated psychosis: impact on 2-year outcome. Psychol Med. 2004;34(2):277–84. https://doi.org/10.1017/s0033291703001156. PMID: 14982133.

    Article  CAS  PubMed  Google Scholar 

  2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596–601. https://doi.org/10.2337/diacare.27.2.596. PMID: 14747245.

    Article  Google Scholar 

  3. Aripiprazole [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2014.

    Google Scholar 

  4. Asenapine [package insert]. Irvine, CA: Merck Sharp & Dohme B. V.; used by Allergan under license; 2017.

    Google Scholar 

  5. Aubry T, Bloch G, Brcic V, Saad A, Magwood O, Abdalla T, Alkhateeb Q, Xie E, Mathew C, Hannigan T, Costello C, Thavorn K, Stergiopoulos V, Tugwell P, Pottie K. Effectiveness of permanent supportive housing and income assistance interventions for homeless individuals in high-income countries: a systematic review. Lancet Public Health. 2020;5(6):e342–60. https://doi.org/10.1016/s2468-2667(20)30055-4.

    Article  PubMed  Google Scholar 

  6. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(2):205–12. https://doi.org/10.4088/jcp.v66n0208. PMID: 15705006.

    Article  PubMed  Google Scholar 

  7. Brexpiprazole [package insert]. Tokyo, Japan: Otsuka Pharmaceutical Co., Ltd., 2017.

    Google Scholar 

  8. Carbon M, Kane JM, Leucht S, Correll CU. Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17(3):330–40. https://doi.org/10.1002/wps.20579. PMID: 30192088; PMCID: PMC6127753.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cariprazine [package insert]. Parsippany, NJ: Actavis Pharma, Inc; 2015.

    Google Scholar 

  10. Clozapine [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2017.

    Google Scholar 

  11. Crawford MJ, Jayakumar S, Lemmey SJ, Zalewska K, Patel MX, Cooper SJ, Shiers D. Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study. Br J Psychiatry. 2014;205(6):473–7. https://doi.org/10.1192/bjp.bp.113.142521. Epub 2014 Oct 16. PMID: 25323141.

    Article  PubMed  Google Scholar 

  12. Daumit GL, Dickerson FB, Wang NY, Dalcin A, Jerome GJ, Anderson CA, Young DR, Frick KD, Yu A, Gennusa JV 3rd, Oefinger M, Crum RM, Charleston J, Casagrande SS, Guallar E, Goldberg RW, Campbell LM, Appel LJ. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med. 2013;368(17):1594–602. https://doi.org/10.1056/NEJMoa1214530. Epub 2013 Mar 21. PMID: 23517118; PMCID: PMC3743095.

  13. Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C, Berk M. A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis. Neurosci Biobehav Rev. 2016;65:185–94. https://doi.org/10.1016/j.neubiorev.2016.03.017. Epub 2016 Apr 9. PMID: 27073049; PMCID: PMC4876729.

  14. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, van Winkel R, Mitchell AJ. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Br J Psychiatry. 2011;199(2):99–105. https://doi.org/10.1192/bjp.bp.110.084665. PMID: 21804146.

    Article  PubMed  Google Scholar 

  15. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2–3):135–57. https://doi.org/10.1016/j.schres.2005.02.010. PMID: 15949648.

    Article  PubMed  Google Scholar 

  16. De Mooij LD, Kikkert M, Theunissen J, Beekman ATF, de Haan L, Duurkoop PWRA, Van HL, Dekker JJM. Dying too soon: excess mortality in severe mental illness. Front Psych. 2019;10:855. https://doi.org/10.3389/fpsyt.2019.00855. PMID: 31920734; PMCID: PMC6918821.

    Article  Google Scholar 

  17. Diehl S, Douglas D, Gay K, Hart J. Road to recovery: employment and mental illness. Arlington: National Alliance on Mental Illness; 2014.

    Google Scholar 

  18. Dieterich M, Irving CB, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2010;10:CD007906. https://doi.org/10.1002/14651858.CD007906.pub2. Update in: Cochrane Database Syst Rev. 2017 Jan 06;1:CD007906. PMID: 20927766; PMCID: PMC4233116.

  19. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47(2):197–207. https://doi.org/10.1016/j.jpsychires.2012.10.005. Epub 2012 Nov 12. PMID: 23153955.

    Article  PubMed  Google Scholar 

  20. Dixon L, Adams C, Lucksted A. Update on family psychoeducation for schizophrenia. Schizophr Bull. 2000;26(1):5–20. https://doi.org/10.1093/oxfordjournals.schbul.a033446. PMID: 10755667.

    Article  CAS  PubMed  Google Scholar 

  21. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM. Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 2000;283(4):506–11. https://doi.org/10.1001/jama.283.4.506. PMID: 10659877.

    Article  CAS  PubMed  Google Scholar 

  22. Diagnostic and Statistical Manual of Mental Disorders: DSM 5. 5th ed., American Psychiatric Association; 2013.

    Google Scholar 

  23. D’Souza DC, Radhakrishnan R, Sherif M, Cortes-Briones J, Cahill J, Gupta S, Skosnik PD, Ranganathan M. Cannabinoids and psychosis. Curr Pharm Des. 2016;22(42):6380–91. https://doi.org/10.2174/1381612822666160826105628. PMID: 27568729.

    Article  CAS  PubMed  Google Scholar 

  24. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA, Evins AE. Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. Psychopharmacology. 2012;219(1):25–34. https://doi.org/10.1007/s00213-011-2373-6.

    Article  CAS  PubMed  Google Scholar 

  25. Eack SM, Hogarty GE, Cho RY, Prasad KM, Greenwald DP, Hogarty SS, Keshavan MS. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry. 2010;67(7):674–82. https://doi.org/10.1001/archgenpsychiatry.2010.63. Epub 2010 May 3. PMID: 20439824; PMCID: PMC3741671.

  26. Fazel S, Långström N, Hjern A, Grann M, Lichtenstein P. Schizophrenia, substance abuse, and violent crime. JAMA. 2009;301(19):2016–23. https://doi.org/10.1001/jama.2009.675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fleishman M. The problem: how many patients live in residential care facilities? Psychiatr Serv. 2004;55(6):620–2. https://doi.org/10.1176/appi.ps.55.6.620. PMID: 15175457.

    Article  PubMed  Google Scholar 

  28. Folsom DP, Hawthorne W, Lindamer L, Gilmer T, Bailey A, Golshan S, Garcia P, Unützer J, Hough R, Jeste DV. Prevalence and risk factors for homelessness and utilization of mental health services among 10,340 patients with serious mental illness in a large public mental health system. Am J Psychiatry. 2005;162(2):370–6. https://doi.org/10.1176/appi.ajp.162.2.370. PMID: 15677603.

    Article  PubMed  Google Scholar 

  29. Fluphenazine [package insert]. Irvine, CA: Gensia Laboratories, Ltd; 1996.

    Google Scholar 

  30. Frayne SM, Halanych JH, Miller DR, et al. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165:2631–8.

    Article  Google Scholar 

  31. Gottesman II. Schizophrenia genesis: the origin of madness. New York: Freeman; 1991.

    Google Scholar 

  32. Haloperidol [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2017.

    Google Scholar 

  33. Hogarty GE. Personal therapy for schizophrenia and related disorders: a guide to individualized treatment. New York: Guilford; 2002. 338 pages

    Google Scholar 

  34. Iloperidone [package insert]. Washington, DC: Vanda Pharmaceuticals Inc.; 2016.

    Google Scholar 

  35. Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS; METS Investigators. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013;170(9):1032–40. https://doi.org/10.1176/appi.ajp.2013.12010127. PMID: 23846733; PMCID: PMC3874085.

  36. Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. Br J Psychiatry. 2014;204(1):20–9. https://doi.org/10.1192/bjp.bp.112.116285. PMID: 24385461.

    Article  CAS  PubMed  Google Scholar 

  37. Jones PB. Adult mental health disorders and their age at onset. Br J Psychiatry Suppl. 2013;54:s5–10. https://doi.org/10.1192/bjp.bp.112.119164. PMID: 23288502.

    Article  CAS  PubMed  Google Scholar 

  38. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH. (Systematic review). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry. 2020;177(9):868–72. https://doi.org/10.1176/appi.ajp.2020.177901. PMID: 32867516.

    Article  PubMed  Google Scholar 

  39. Kisely S, Smith M, Lawrence D, Cox M, Campbell LA, Maaten S. Inequitable access for mentally ill patients to some medically necessary procedures. CMAJ. 2007;176(6):779–84. https://doi.org/10.1503/cmaj.060482. PMID: 17353530; PMCID: PMC1808525.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kisely S, Crowe E, Lawrence D. Cancer-related mortality in people with mental illness. JAMA Psychiat. 2013;70:209–17.

    Article  Google Scholar 

  41. Laursen TM, Mortensen PB, MacCabe JH, Cohen D, Gasse C. Cardiovascular drug use and mortality in patients with schizophrenia or bipolar disorder: a Danish population-based study. Psychol Med. 2014;44(8):1625–37. https://doi.org/10.1017/S003329171300216X. Epub 2013 Nov 18. PMID: 24246137.

    Article  CAS  PubMed  Google Scholar 

  42. Li R, Ma X, Wang G, Yang J, Wang C. Why sex differences in schizophrenia? J Transl Neurosci (Beijing). 2016;1(1):37–42. PMID: 29152382; PMCID: PMC5688947.

    Google Scholar 

  43. Lord O, Malone D, Mitchell AJ. Receipt of preventive medical care and medical screening for patients with mental illness: a comparative analysis. Gen Hosp Psychiatry. 2010;32(5):519–43. https://doi.org/10.1016/j.genhosppsych.2010.04.004. Epub 2010 Aug 5. PMID: 20851274.

    Article  PubMed  Google Scholar 

  44. Loxapine [package insert]. Corona, CA: Watson Pharmaceuticals; 2017.

    Google Scholar 

  45. Lumateperone [package insert]. New York, NY: Intra-Cellular Therapies, Inc.; 2019.

    Google Scholar 

  46. Lupu AM, MacCamy KL, Gannon JM, Brar JS, Chengappa KR. Less is more: deprescribing anticholinergic medications in persons with severe mental illness. Ann Clin Psychiatry. 2021;33(1):e1–e13. https://doi.org/10.12788/acp.0019. Epub ahead of print. PMID: 33529289.

  47. Lurasidone [package insert]. Chuo-ku, Osaka, Japan: Dainippon Sumitomo Pharma Co. Ltd.; 2013.

    Google Scholar 

  48. Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35(7):1520–30. https://doi.org/10.1038/npp.2010.21. Epub 2010 Mar 24. PMID: 20336059; PMCID: PMC3055458.

  49. Marcsisin MJ, Rosenstock JB, Gannon JM, editors. Schizophrenia and related disorders. Oxford University Press; 2017.

    Google Scholar 

  50. Mitchell AJ, Pereira IE, Yadegarfar M, Pepereke S, Mugadza V, Stubbs B. Breast cancer screening in women with mental illness: comparative meta-analysis of mammography uptake. Br J Psychiatry. 2014;205(6):428–35. https://doi.org/10.1192/bjp.bp.114.147629. PMID: 25452600.

    Article  PubMed  Google Scholar 

  51. McDonagh MS, Dana T, Selph S, Devine EB, Cantor A, Bougatsos C, Blazina I, Grusing S, Fu R, Kopelovich SL, Monroe-DeVita M, Haupt DW. Treatments for schizophrenia in adults: a systematic review [Internet]. Rockville: Agency for Healthcare Research and Quality (US); 2017 Oct. Report No.: 17(18)-EHC031-EF. PMID: 29537779.

    Google Scholar 

  52. Myles N, Myles H, Xia S, Large M, Kisely S, Galletly C, Bird R, Siskind D. Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand. 2018;138(2):101–9. https://doi.org/10.1111/acps.12898. Epub 2018 May 21. PMID: 29786829.

    Article  CAS  PubMed  Google Scholar 

  53. Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1–3):15–22. https://doi.org/10.1016/j.schres.2006.06.026. Epub 2006 Aug 1. PMID: 16884895.

    Article  PubMed  Google Scholar 

  54. Nimgaonkar VL, Fujiwara TM, Dutta M, Wood J, Gentry K, Maendel S, Morgan K, Eaton J. Low prevalence of psychoses among the Hutterites, an isolated religious community. Am J Psychiatry. 2000;157(7):1065–70. https://doi.org/10.1176/appi.ajp.157.7.1065. PMID: 10873912.

    Article  CAS  PubMed  Google Scholar 

  55. Olanzapine [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.

    Google Scholar 

  56. Paliperidone [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2009.

    Google Scholar 

  57. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62(3):247–53. https://doi.org/10.1001/archpsyc.62.3.247.

    Article  PubMed  Google Scholar 

  58. Perphenazine. [package insert]. Princeton, NJ: Sandoz Inc.

    Google Scholar 

  59. Pimozide. [package insert]. Sellersville, PA: Gate Pharmaceuticals, Div. of Teva Pharmaceuticals.

    Google Scholar 

  60. Potkin SG, Kane JM, Correll CU, Lindenmayer JP, Agid O, Marder SR, Olfson M, Howes OD. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. NPJ Schizophr. 2020;6(1):1. https://doi.org/10.1038/s41537-019-0090-z. PMID: 31911624; PMCID: PMC6946650.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Quetiapine [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2013.

    Google Scholar 

  62. Ramsay CE, Goulding SM, Broussard B, Cristofaro SL, Abedi GR, Compton MT. Prevalence and psychosocial correlates of prior incarcerations in an urban, predominantly African-American sample of hospitalized patients with first-episode psychosis. J Am Acad Psychiatry Law. 2011;39(1):57–64.

    PubMed  PubMed Central  Google Scholar 

  63. Risperidone [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.

    Google Scholar 

  64. Rogers E, Kash- MacDonald M, Olschewski A. Systematic Review of Supported Housing Literature, 1993–2008. Boston: Boston University, Sargent College, Center for Psychiatric Rehabilitation; 2009.

    Google Scholar 

  65. Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, Lieberman J. CATIE Study Investigators Group. Barriers to employment for people with schizophrenia. Am J Psychiatry. 2006;163(3):411–7. https://doi.org/10.1176/appi.ajp.163.3.411. PMID: 16513861.

    Article  PubMed  Google Scholar 

  66. Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, Riedel M, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. Am J Psychiatry. 2015;172(7):617–29. https://doi.org/10.1176/appi.ajp.2015.14101329. Epub 2015 Jun 5. PMID: 26046338.

    Article  PubMed  Google Scholar 

  67. Schneider M, Regente J, Greiner T, Lensky S, Bleich S, Toto S, Grohmann R, Stübner S, Heinze M. Neuroleptic malignant syndrome: evaluation of drug safety data from the AMSP program during 1993–2015. Eur Arch Psychiatry Clin Neurosci. 2020;270(1):23–33. https://doi.org/10.1007/s00406-018-0959-2. Epub 2018 Nov 30. PMID: 30506147.

    Article  PubMed  Google Scholar 

  68. Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. Diabetes Obes Metab. 2019;21(2):293–302. https://doi.org/10.1111/dom.13522. Epub 2018 Oct 7. PMID: 30187620.

    Article  CAS  PubMed  Google Scholar 

  69. Stein LI, Test MA. Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation. Arch Gen Psychiatry. 1980;37(4):392–7. https://doi.org/10.1001/archpsyc.1980.01780170034003. PMID: 7362425.

    Article  CAS  PubMed  Google Scholar 

  70. Stubbs B, Williams J, Gaughran F, Craig T. How sedentary are people with psychosis? A systematic review and meta-analysis. Schizophr Res. 2016;171(1–3):103–9. https://doi.org/10.1016/j.schres.2016.01.034. Epub 2016 Jan 21. PMID: 26805414.

    Article  PubMed  Google Scholar 

  71. Substance Abuse and Mental Health Services Administration. National consensus on mental health recovery and systems transformation. Rockville: Department of Health and Human Services; 2005.

    Google Scholar 

  72. Takeuchi H, Siu C, Remington G, Fervaha G, Zipursky RB, Foussias G, Agid O. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019;44(6):1036–1042. doi: https://doi.org/10.1038/s41386-018-0278-3. Epub 2018 Nov 22. PMID: 30514883; PMCID: PMC6462044.

  73. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophr Res. 2009;110(1–3):1–23. https://doi.org/10.1016/j.schres.2009.03.005. Epub 2009 Mar 27. PMID: 19328655.

    Article  PubMed  Google Scholar 

  74. Thorazine [package insert]. Greenville, SC: PAI Pharmaceutical Associates; 1998.

    Google Scholar 

  75. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013, Issue 2. Art. No.: CD007253. https://doi.org/10.1002/14651858.CD007253.pub3. Accessed 20 February 2021.

  76. Varshney M, Mahapatra A, Krishnan V, Gupta R, Deb KS. Violence and mental illness: what is the true story? J Epidemiol Community Health. 2016;70(3):223–5. https://doi.org/10.1136/jech-2015-205546. Epub 2015 Aug 28. PMID: 26320232; PMCID: PMC4789812.

  77. Wildgust HJ, Hodgson R, Beary M. The paradox of premature mortality in schizophrenia: new research questions. J Psychopharmacol. 2010;24(4 Suppl):9–15. https://doi.org/10.1177/1359786810382149. PMID: 20923916; PMCID: PMC2951588.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Wykes T, Huddy V, Cellard C, McGurk SR, Czobor P. A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes. Am J Psychiatry. 2011;168(5):472–85. https://doi.org/10.1176/appi.ajp.2010.10060855. Epub 2011 Mar 15. PMID: 21406461.

    Article  PubMed  Google Scholar 

  79. Ziaaddini H, Kheradmand A, Vahabi M. Prevalence of cigarette smoking in schizophrenic patients compared to other hospital admitted psychiatric patients. Addict Health. 2009 Summer;1(1):38–42. PMID: 24494081; PMCID: PMC3905500.

    Google Scholar 

  80. Ziprasidone [package insert]. New York, NY: Pfizer; 2014.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA

    Robert Hudak & Jessica M. Gannon

Authors
  1. Robert Hudak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jessica M. Gannon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert Hudak .

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hudak, R., Gannon, J.M. (2022). Schizophrenia. In: Handbook of Psychiatric Disorders in Adults in the Primary Care Setting. Current Clinical Practice. Humana, Cham. https://doi.org/10.1007/978-3-030-98709-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-98709-1_4

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-98708-4

  • Online ISBN: 978-3-030-98709-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation